On June 11, 2024, WuXi Biologics submitted a disclosure report for the following day, disclosing changes in its issued or treasury shares. The report showed that the company exercised options under a stock option plan from June 3 to June 11, 2024, increasing its shares by 472,020, accounting for a tiny percentage of the issued shares. In addition, the company repurchased and cancelled 109,868,000 shares on June 11, 2024, accounting for 2.57756% of the issued shares. On the same day, the company also repurchased 1,810,000 shares, which are intended to be cancelled but have not yet been cancelled. The company confirmed that all changes in shareholding have been approved by the board of directors and comply with relevant listing rules and legal provisions.

On June 11, 2024, WuXi Biologics submitted a disclosure report for the following day, disclosing changes in its issued or treasury shares. The report showed that the company exercised options under a stock option plan from June 3 to June 11, 2024, increasing its shares by 472,020, accounting for a tiny percentage of the issued shares. In addition, the company repurchased and cancelled 109,868,000 shares on June 11, 2024, accounting for 2.57756% of the issued shares. On the same day, the company also repurchased 1,810,000 shares, which are intended to be cancelled but have not yet been cancelled. The company confirmed that all changes in shareholding have been approved by the board of directors and comply with relevant listing rules and legal provisions.